Immune cell therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new immune cell therapy (EVM16) given alone or with another drug (tislelizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that came back or spread after other treatments and cannot be removed by surgery.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are generally up and active (able to care for yourself, out of bed more than half the day).
- You are willing to provide a sample of your tumor tissue (from a past biopsy or a new one) for the study drug to be made.
- You do not have an active autoimmune disease, a serious infection, or other major health problems that are not under control.
- You have not had a stroke, certain heart issues, or a history of severe lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy that uses your own immune cells (T-cells) specially modified to target your tumor. It is for people with advanced solid tumors who have run out of standard treatment options.
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
This trial tests a new drug called EVM14, alone or with other treatments, for people with advanced solid tumors that can't be removed by surgery or have spread. It aims to see if the drug is safe and helps shrink or control the cancer.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
This trial tests a combination of two cell-based therapies (SCTB41 and SCTB39-1) with or without standard cancer treatments for advanced solid tumors. The goal is to see if this approach helps slow or shrink tumors while being safe enough to use in patients.
This trial tests a treatment that takes immune cells from your tumor, multiplies them in a lab, and gives them back to you to fight the cancer. It is for people with advanced solid tumors who have tried other treatments or cannot have them.
Hear when a new Advanced or Recurrent Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.